Novo Nordisk announced that its next-generation experimental obesity drug achieved a 12.4% average weight loss in a late-stage study, outperforming a rival treatment from Eli Lilly. Following these results, the company's CEO expressed openness to mergers and acquisitions to further strengthen its weight-loss drug pipeline. Additionally, the CEO told the Financial Times that Novo Nordisk is considering upgrading its New York listing. This potential move aims to increase the Danish drugmaker's profile and visibility within the United States.
